A phase II study of liposomal lurtotecan (OSI-211) in patients with topotecan resistant ovarian cancer-Reference-Cited by-同舟云学术

A phase II study of liposomal lurtotecan (OSI-211) in patients with topotecan resistant ovarian cancer

Published:2004-04 Issue:1 Volume:93 Page:229-232
ISSN:0090-8258
Container-title:Gynecologic Oncology
language:en
Short-container-title:Gynecologic Oncology

Author:

Seiden Michael V,Muggia Franco,Astrow Allan,Matulonis Ursula,Campos Susanna,Roche Maria,Sivret Julia,Rusk Jason,Barrett Emma

Publisher

Elsevier BV

Subject

Obstetrics and Gynaecology,Oncology

Reference14 articles.

1. Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer;ten Bokkel Huinink;J. Clin. Oncol.,1997

2. Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan;Gordon;J. Clin. Oncol.,2001

3. Salvage therapy for ovarian cancer;Garcia;Curr. Oncol. Rep.,1999

4. Chemotherapy for recurrent epithelial ovarian cancer previously treated with platinum—A systematic review of the evidence from randomized trials;Fung;Eur. J. Gynaecol. Oncol.,2002

5. Part II: chemotherapy for epithelial ovarian cancer-treatment of recurrent disease;Harries;Lancet Oncol.,2002

Cited by 77 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Multifunctional and stimuli-responsive liposomes in hepatocellular carcinoma diagnosis and therapy;Translational Oncology;2024-07

2. Recent advances in liposome-based targeted cancer therapy;Journal of Liposome Research;2023-10-09

3. Development and Perspectives: Multifunctional Nucleic Acid Nanomedicines for Treatment of Gynecological Cancers;Small;2023-07-30

4. Recent advances in access to overcome cancer drug resistance by nanocarrier drug delivery system;Cancer Drug Resistance;2023

5. Scaffolds in cytotoxic drugs and novel antitumor molecules interacting with nucleic acids;Privileged Scaffolds in Drug Discovery;2023